White Paper

Safety First: Controlling Occupational Exposure In Oncology Drug Development

By Joe Galati, PhD, Sr. Director, Global Toxicology Services, Thermo Fisher Scientific

feature

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs, targeted therapeutics that zero in on specific parts of cancer cells while sparing normal cells have become mainstream cancer treatments. Delivering on the potential of small molecule oncology therapies requires understanding and embracing safe handling practices and containment technology. It also requires maintaining, continuously assessing, and aligning infrastructure, technology, and the expertise of stakeholders involved in the development process.

As more information becomes available through pre-clinical animal toxicity studies and human clinical trials, novel compounds that were originally classified as highly potent because of the absence of toxicity data may be downgraded if the science supports the change. Discover how classifying exposure limits for a given substance enables manufacturers to identify and implement the best control strategy to protect operators and drug products to reliably and consistently ensure worker and patient safety.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online